Loading...
•
Dec 31, 2023
MannKind Q4 2023 Earnings Report
Reported a robust fourth quarter with significant revenue growth and a strong cash position.
Key Takeaways
MannKind Corporation reported a strong fourth quarter in 2023, with total revenues of $58 million, a 62% increase compared to 2022. The company's net income was $1 million, with a non-GAAP net income of $7 million. MannKind ended the year with a robust cash position of over $300 million, positioning it well for upcoming clinical data read-outs and the advancement of its MNKD-101 and MNKD-201 programs.
Total revenues for Q4 2023 reached $58 million, a 62% increase compared to the same period in 2022.
Net income for Q4 2023 was $1 million, with non-GAAP net income at $7 million.
Cash and cash equivalents and investments stood at $302 million as of December 31, 2023.
Afrezza net revenue increased by 29% due to higher product demand and higher price.
Revenue by Segment
Forward Guidance
MannKind is focused on upcoming data read-outs for Afrezza and advancing MNKD-101 into phase 3 and MNKD-201 into phase 1 in the first half of 2024.
Positive Outlook
- Enrollment completed in February 2024 for Afrezza INHALE-1 (pediatric phase 3 clinical trial)
- Primary endpoint analysis in 4Q 2024 for Afrezza INHALE-1
- Full results in 1H 2025 for Afrezza INHALE-1
- FDA submission for label expansion expected in 2025 for Afrezza INHALE-1
- Phase 3 development program aligned with the FDA for MNKD-101 – IND expected to be filed in 1Q 2024
Challenges Ahead
- Risks associated with manufacturing and supply
- Risks associated with developing product candidates
- Potential delays in clinical trial timelines
- Uncertainties in regulatory approvals
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...